Lukas Biomedical (ROCO:6814) Other Stockholders Equity: NT$-0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6814 Lukas Biomedical Inc ROCO:6814
65 GF Score
Price NT$23.40
GF Value NT$21.74
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Lukas Biomedical Other Stockholders Equity?

Lukas Biomedical ROCO:6814 65 Other Stockholders Equity is NT$-0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:6814 with a GF Score™ of 65/100 and a GF Value™ of NT$21.74 (Fairly Valued). The stock has 7 warning signs investors should review.

Lukas Biomedical's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$-0.0 Mil.

Lukas Biomedical's quarterly Other Stockholders Equity stayed the same from Dec. 2024 (NT$0.0 Mil) to Jun. 2025 (NT$0.0 Mil) but then declined from Jun. 2025 (NT$0.0 Mil) to Dec. 2025 (NT$-0.0 Mil).

Lukas Biomedical's annual Other Stockholders Equity increased from Dec. 2023 (NT$-0.0 Mil) to Dec. 2024 (NT$0.0 Mil) but then declined from Dec. 2024 (NT$0.0 Mil) to Dec. 2025 (NT$-0.0 Mil).

Lukas Biomedical Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical Other Stockholders Equity Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 0.00 -0.00 0.00 -0.00

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 -0.00
ROCO:6814
65GF Score
Lukas Biomedical Inc ROCO:6814
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$-0.0 Mil mean?
Lukas Biomedical (ROCO:6814) has a Other Stockholders Equity of NT$-0.0 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Lukas Biomedical and its competitors.
Is Lukas Biomedical's Other Stockholders Equity too high?
Lukas Biomedical's current Other Stockholders Equity is NT$-0.0 Mil. Overall, Lukas Biomedical has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Other Stockholders Equity compare to VRTX and REGN?
Lukas Biomedical's Other Stockholders Equity of NT$-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Lukas Biomedical and its competitors. Lukas Biomedical's current Other Stockholders Equity is NT$-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Fairly Valued. The stock's GF Value™ is NT$21.74, compared to a current price of NT$23.40 — trading 7.6% above its estimated fair value. The current Other Stockholders Equity is NT$-0.0 Mil. Lukas Biomedical's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Other Stockholders Equity is NT$-0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$23.40 is trading 7.6% above its estimated GF Value™ of NT$21.74. GuruFocus considers Lukas Biomedical to be Fairly Valued.

Key valuation signals for ROCO:6814:

  • Other Stockholders Equity: NT$-0.0 Mil
  • GF Value™: NT$21.74 vs. price of NT$23.40 (7.6% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
65GF Score

Get the complete analysis for ROCO:6814

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.40
Price
NT$21.74
GF Value